Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
HIGHLIGHTSMDMA damages serotonergic system in primates and rats and dopaminergic system in mice.METH damages the dopaminergic system in all animal species including humans.The nigrostriatal system is more vulnerable than the mesolimbic system.Within the striatum the striosomes are more vulnerable than the matrix.METH kills dopamine neurons as demonstrated by silver‐staining in rodents.METH reduces DAT binding sites and motor skills in human addicts. ABSTRACT Amphetamine‐related drugs, such as 3,4‐methylenedioxymethamphetamine (MDMA) and methamphetamine (METH), are popular recreational psychostimulants. Several preclinical studies have demonstrated that, besides having the potential for abuse, amphetamine‐related drugs may also elicit neurotoxic and neuroinflammatory effects. The neurotoxic potentials of MDMA and METH to dopaminergic and serotonergic neurons have been clearly demonstrated in both rodents and non‐human primates. This review summarizes the species‐specific cellular and molecular mechanisms involved in MDMA and METH‐mediated neurotoxic and neuroinflammatory effects, along with the most important behavioral changes elicited by these substances in experimental animals and humans. Emphasis is placed on the neuropsychological and neurological consequences associated with the neuronal damage. Moreover, we point out the gap in our knowledge and the need for developing appropriate therapeutic strategies to manage the neurological problems associated with amphetamine‐related drug abuse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 1×
“As mentioned above, glial cells, particularly microglia, are the primary modulators of inflammation in the CNS (Stoll and Jander, 1999; Block et al., 2007) as they constantly ‘‘survey’’ their environment and utilize their constitutively expressed surface receptors to trigger or amplify responses to…”
BackgroundThe physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration
Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144 · cited 3×
“This increased proinflammatory response may result in a delayed and progressive loss in dopaminergic neurons in the SN, similar to that seen in PD, strengthening the suggestion that unregulated neuroinflammation could lead to neurodegeneration (Qin et al., 2007).”
BackgroundResultLinnoila, M., Virkkunen, M., Scheinin, M., Nuutila, A., Rimon, R., & Goodwin, F. K. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90344-2 · Cited by 1,308
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
Distinct functions of the two isoforms of dopamine D2 receptors
Usiello, A., Baik, J.-H., Rougé-Pont, F., Picetti, R., Dierich, A., LeMeur, M., Piazza, P. V., & Borrelli, E. (2000) · Nature · doi:10.1038/35041572 · Cited by 717 · cited 2×
“control of DA release and regulation of extrasynaptic DA levels), whereas D2-L is mainly a postsynaptic isoform (Usiello et al., 2000; De Mei et al., 2009).”
BackgroundMcCann, U. D., Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., & Ricaurte, G. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-20-08417.1998 · Cited by 602 · cited 2×
“Other reports of neurotoxic effects of METH in human abusers indicate poor motor performance associated with DAT loss in the caudate nucleus and putamen (Volkow et al., 2001a,b; McCann et al., 1998).”
BackgroundInvited Review Free radicals and the pathobiology of brain dopamine systems
Cadet, J. L., & Brannock, C. (1998) · Neurochemistry International · doi:10.1016/s0197-0186(97)00031-4 · Cited by 499
Harrison, A. A., Everitt, B. J., & Robbins, T. W. (1997) · Psychopharmacology · doi:10.1007/s002130050410 · Cited by 452 · cited 2×
“Furthermore, reduced serotonergic activity is associated with heightened impulsivity and enhanced sensation seeking (Linnoila et al., 1983), and lesions of the serotonergic neurons elicit anxiolytic effects and increased impulsivity in rats (Harrison et al., 1997; Soderpalm and Svensson, 1999).”
BackgroundVollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00013-x · Cited by 448 · cited 4×
“Remarkably, hypertension, in combination with coagulopathy, might be potentially responsible for the cerebral insults induced by MDMA, as suggested by a single case report (Vollenweider et al., 1998).”
BackgroundInfluential
Research works printed but not linked: 319
- Adori, 2006, Damage of serotonergic axons and immunolocalization of Hsp27, Hsp72, and Hsp90 molecular chaperones after a single dose of MDMA administration in dark agouti rat: temporal, spatial, and cellular patterns, J. Comp. Neurol., 497, 251, 10.1002/cne.20994 · DOI
- Afonso-Oramas, 2009, Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease, Neurobiol. Dis., 36, 494, 10.1016/j.nbd.2009.09.002 · DOI · Paper page
- Aguirre, 1999, Alpha-lipoic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity, NeuroReport, 10, 3675, 10.1097/00001756-199911260-00039 · DOI
- Albers, 1995, Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents, J. Pharmacol. Exp. Ther., 275, 1104, 10.1016/S0022-3565(25)12160-5 · DOI · Paper page
- Alles, 1993, The comparative physiological actions of the dl-B-phenylisopropylamines. I. Pressor effect and toxicity, J. Pharmacol. Exp. Ther., 47, 339, 10.1016/S0022-3565(25)08045-0 · DOI
- Aloisi, 2001, Immune function of microglia, Glia, 36, 165, 10.1002/glia.1106 · DOI · Paper page
- Alves, 2007, Monoamine oxidase-B mediates ecstasy-induced neurotoxic effects to adolescent rat brain mitochondria, J. Neurosci., 27, 10203, 10.1523/JNEUROSCI.2645-07.2007 · DOI
- Andres, 2015, Methamphetamine acutely inhibits voltage-gated calcium channels but chronically up-regulates L-type channels, J. Neurochem., 10.1111/jnc.13104 · DOI
- Angoa-Pérez, 2013, Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA, J. Neurochem., 125, 102, 10.1111/jnc.12114 · DOI
- Angulo, 2004, Antagonists of the neurokinin-1 or dopamine D1 receptors confer protection from methamphetamine on dopamine terminals of the mouse striatum, Ann. N. Y. Acad. Sci., 1025, 171, 10.1196/annals.1316.022 · doi:10.1196/annals.1316.022
- Anneken, 2013, MDMA increases glutamate release and reduces parvalbumin-positive GABAergic cells in the dorsal hippocampus of the rat: role of cyclooxygenase, J. Neuroimmune Pharmacol., 8, 58, 10.1007/s11481-012-9420-x · DOI · Paper page
- Ares-Santos, 2012, Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine, Neurobiol. Dis., 45, 810, 10.1016/j.nbd.2011.11.005 · DOI · Paper page
- Ares-Santos, 2013, The role of dopamine receptors in the neurotoxicity of methamphetamine, J. Intern. Med., 273, 437, 10.1111/joim.12049 · DOI · Paper page
- Ares-Santos, 2014, Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining, Neuropsychopharmacology, 39, 1066, 10.1038/npp.2013.307 · DOI
- Bai, 2001, Serotonergic neurotoxicity of 3,4-(+/−)-methylenedioxyamphetamine and 3,4-(+/−)-methylenedioxymethamphetamine (Ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase, Chem. Res. Toxicol., 14, 863, 10.1021/tx010011l · DOI
- Barbosa, 2014, “Ecstasy”-induced toxicity in SH-SY5Y differentiated cells: role of hyperthermia and metabolites, Arch. Toxicol., 88, 515, 10.1007/s00204-013-1147-9 · DOI
- Barcia, 2011, IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease, Cell. Death Dis., 2, e142, 10.1038/cddis.2011.17 · DOI · Paper page
- Battaglia, 1987, 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites, J. Pharmacol. Exp. Ther., 242, 911, 10.1016/S0022-3565(25)39191-3 · DOI · Paper page
- Battaglia, 2002, Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity, J. Neurosci., 22, 2135, 10.1523/JNEUROSCI.22-06-02135.2002 · DOI · Paper page
- Bauernfeind, 2011, Human Ecstasy use is associated with increased cortical excitability: an fMRI study, Neuropsychopharmacology, 36, 1127, 10.1038/npp.2010.244 · DOI
- Beauvais, 2011, Involvement of dopamine receptors in binge methamphetamine-induced activation of endoplasmic reticulum and mitochondrial stress pathways, PLoS ONE, 6, e28946, 10.1371/journal.pone.0028946 · DOI · Paper page
- Benamar, 2008, A new brain area affected by 3,4 methylenedioxymethamphetamine: a microdialysis-biotelemetry study, Eur. J. Pharmacol., 596, 84, 10.1016/j.ejphar.2008.08.001 · doi:10.1016/j.ejphar.2008.08.001
- Benningfield, 2013, Brain serotonin function in MDMA (ecstasy) users: evidence for persisting neurotoxicity, Neuropsychopharmacology, 38, 253, 10.1038/npp.2012.178 · DOI
- Benzenhöfer, 2010, Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin, Addiction, 105, 1355, 10.1111/j.1360-0443.2010.02948.x · DOI
- Bezard, 2006, 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease, Neurobiol. Dis., 23, 77, 10.1016/j.nbd.2006.02.003 · DOI
- Bourne, 2001, SCH 23390 the first selective dopamine D1-like receptor antagonist, CNS Drug Rev., 7, 399, 10.1111/j.1527-3458.2001.tb00207.x · DOI · Paper page
- Bowyer, 2001, Phenobarbital and dizocilpine can block methamphetamine-induced neurotoxicity in mice by mechanisms that are independent of thermoregulation, Brain Res., 919, 179, 10.1016/S0006-8993(01)03051-7 · doi:10.1016/s0006-8993(01)03051-7
- Bowyer, 2008, Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood–brain barrier in the caudate-putamen from acute methamphetamine exposure, Synapse, 62, 193, 10.1002/syn.20478 · DOI · Paper page
- Brodkin, 1993, Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity, Pharmacol. Biochem. Behav., 45, 647, 10.1016/0091-3057(93)90520-4 · DOI
- Broening, 2005, Interactions of dopamine D1 and D2 receptor antagonists with d-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions, Synapse, 56, 84, 10.1002/syn.20130 · DOI
- Bronstein, 1995, Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality, J. Pharmacol. Exp. Ther., 274, 943, 10.1016/S0022-3565(25)10672-1 · DOI
- Brown, 2003, Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress, Pharmacol. Ther., 99, 45, 10.1016/S0163-7258(03)00052-4 · DOI · Paper page
- Brown, 2005, Methamphetamine induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite, J. Neurochem., 95, 429, 10.1111/j.1471-4159.2005.03379.x · DOI · Paper page
- Brown, 2006, Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression, J. Neurochem., 98, 495, 10.1111/j.1471-4159.2006.03902.x · doi:10.1111/j.1471-4159.2006.03902.x
- Bruno, 1993, Excitatory amino acids and neurotoxicity, Funct. Neurol., 8, 279
- Buchert, 2006, Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users, Eur. J. Nucl. Med. Mol. Imaging, 33, 188, 10.1007/s00259-005-1850-8 · DOI
- Burke, 1993, Relative loss of the striatal striosome compartment, defined by calbindin-D28k immunostaining, following developmental hypoxic-ischemic injury, Neuroscience, 56, 305, 10.1016/0306-4522(93)90333-B · DOI
- Büttner, 2006, Neuropathological alterations in drug abusers: the involvement of neurons, glial, and vascular systems, Forensic Sci. Med. Pathol., 2, 115, 10.1385/FSMP:2:2:115 · DOI
- Büttner, 2011, Review: the neuropathology of drug abuse, Neuropathol. Appl. Neurobiol., 37, 118, 10.1111/j.1365-2990.2010.01131.x · DOI · Paper page
- Cadet, 2001, Involvement of free radicals in MDMA-induced neurotoxicity in mice, Ann. Med. Interne (Paris), 152, IS57
- Cai, 2008, The combination of methamphetamine and of the HIV protein, Tat, induces death of the human neuroblastoma cell line, SH-SY5Y, Synapse, 62, 551, 10.1002/syn.20512 · doi:10.1002/syn.20512
- Caligiuri, 2005, Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?, Neuropsychopharmacology, 30, 2125, 10.1038/sj.npp.1300859 · DOI
- Callaghan, 2010, Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders, Mov. Disord., 25, 2333, 10.1002/mds.23263 · DOI · Paper page
- Callaghan, 2012, Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs, Drug Alcohol Depend., 120, 35, 10.1016/j.drugalcdep.2011.06.013 · DOI · Paper page
- Callier, 2003, Evolution and cell biology of dopamine receptors in vertebrates, Biol. Cell, 95, 489, 10.1016/S0248-4900(03)00089-3 · DOI · Paper page
- Capela, 2006, Neurotoxicity of Ecstasy metabolites in rat cortical neurons, and influence of hyperthermia, J. Pharmacol. Exp. Ther., 316, 53, 10.1124/jpet.105.092577 · DOI
- Capela, 2006, Ecstasy-induced cell death in cortical neuronal cultures is serotonin 2A-receptor dependent and potentiated under hyperthermia, Neuroscience, 139, 1069, 10.1016/j.neuroscience.2006.01.007 · DOI
- Capela, 2009, Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview, Mol. Neurobiol., 39, 210, 10.1007/s12035-009-8064-1 · DOI · Paper page
- Cappon, 2000, Time-course of methamphetamine-induced neurotoxicity in rat caudate-putamen after single-dose treatment, Brain Res., 863, 106, 10.1016/S0006-8993(00)02107-7 · DOI
- Carmena, 2015, Methamphetamine-induced toxicity in indusium griseum of mice is associated with astro- and microgliosis, Neurotox. Res., 27, 209, 10.1007/s12640-014-9505-9 · DOI
- Chang, 2007, Structural and metabolic brain changes in the striatum associated with methamphetamine abuse, Addiction, 102, 16, 10.1111/j.1360-0443.2006.01782.x · DOI · Paper page
- Chen, 2004, D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade, J. Biol. Chem., 279, 39317, 10.1074/jbc.M403891200 · DOI · Paper page
- Chen, 2013, RNA interference targeting α-synuclein attenuates methamphetamine-induced neurotoxicity in SH-SY5Y cells, Brain Res., 1521, 59, 10.1016/j.brainres.2013.05.016 · DOI
- Chipana, 2008, Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents, Neuropharmacology, 54, 1254, 10.1016/j.neuropharm.2008.04.003 · DOI
- Chomchai, 2010, Methamphetamine abuse during pregnancy and its health impact on neonates born at Siriraj Hospital, Bangkok, Thailand, Southeast Asian J. Trop. Med. Public Health, 35, 228
- Christine, 2010, Parkinsonism in patients with a history of amphetamine exposure, Mov. Disord., 25, 228, 10.1002/mds.22915 · DOI
- Chu, 2010, Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release, J. Neurochem., 115, 325, 10.1111/j.1471-4159.2010.06922.x · DOI
- Cisneros, 2012, HIV-1, methamphetamine and astrocyte glutamate regulation: combined excitotoxic implications for neuro-AIDS, Curr. HIV Res., 10, 392, 10.2174/157016212802138832 · DOI
- Colado, 1995, The hyperthermic and neurotoxic effects of “ecstasy” (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the dark agouti (DA) rat, a model of the cyp2d6 poor metabolizer phenotype, Br. J. Pharmacol., 115, 1281, 10.1111/j.1476-5381.1995.tb15037.x · DOI · Paper page
- Colado, 1998, Role of hyperthermia in the protective action of chlomethiazole against MDMA (“ecstasy”)-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR, Br. J. Pharmacol., 124, 479, 10.1038/sj.bjp.0701859 · DOI
- Colado, 2001, A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on dopamine neurones in mouse brain, Br. J. Pharmacol., 134, 1711, 10.1038/sj.bjp.0704435 · DOI
- Commins, 1987, Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain, J. Pharmacol. Exp. Ther., 241, 338, 10.1016/S0022-5347(25)00317-9 · DOI · Paper page
- Costa, 2013, MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice, Mov. Disord., 28, 1957, 10.1002/mds.25646 · DOI
- Costa, 2014, MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex, Psychopharmacology (Berl.), 231, 4007, 10.1007/s00213-014-3536-z · DOI
- Cox, 2014, Behavioral and neurochemical effects of repeated MDMA administration during late adolescence in the rat, Prog. Neuropsychopharmacol. Biol. Psychiatry, 48, 229, 10.1016/j.pnpbp.2013.09.021 · DOI
- Cozzi, 1999, Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines, Eur. J. Pharmacol., 381, 63, 10.1016/S0014-2999(99)00538-5 · DOI · Paper page
- Crawford, 2006, Neonatal 3,4-methylenedioxymethamphetamine (MDMA) exposure alters neuronal protein kinase A activity, serotonin and dopamine content, and [35S]GTPgammaS binding in adult rats, Brain Res., 1077, 178, 10.1016/j.brainres.2006.01.017 · DOI
- Cubells, 1994, Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress, J. Neurosci., 14, 2260, 10.1523/JNEUROSCI.14-04-02260.1994 · DOI · Paper page
- Cunningham, 2003, Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions, Addiction, 98, 1229, 10.1046/j.1360-0443.2003.00450.x · DOI
- Cunningham, 2008, Impact of methamphetamine precursor legislation, a suppression policy, on the demand for drug treatment, Soc. Sci. Med., 66, 1463, 10.1016/j.socscimed.2007.12.006 · DOI
- Cunningham, 2008, Methamphetamine suppression and route of administration: precursor regulation impacts on snorting, smoking, swallowing and injecting, Addiction, 103, 1174, 10.1111/j.1360-0443.2008.02208.x · DOI
- Curtin, 2015, Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment, Drug Alcohol Depend., 146, 30, 10.1016/j.drugalcdep.2014.10.027 · DOI · Paper page
- Dafters, 1998, Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”) but not by fenfluramine, Psychopharmacology (Berl.), 138, 207, 10.1007/s002130050664 · DOI
- Darmopil, 2009, Genetic inactivation of dopamine D1 but not D2 receptors inhibits l-DOPA-induced dyskinesia and histone activation, Biol. Psychiatry, 66, 603, 10.1016/j.biopsych.2009.04.025 · DOI · Paper page
- Darvas, 2009, Restriction of dopamine signaling to the dorsolateral striatum is sufficient for many cognitive behaviors, Proc. Natl. Acad. Sci. U. S. A., 106, 14664, 10.1073/pnas.0907299106 · DOI · Paper page
- Darvas, 2010, Restricting dopaminergic signaling to either dorsolateral or medial striatum facilitates cognition, J. Neurosci., 30, 1158, 10.1523/JNEUROSCI.4576-09.2010 · DOI · Paper page
- Daumann, 2004, Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: evidence from an 18-month longitudinal functional magnetic resonance imaging study, Biol. Psychiatry, 56, 349, 10.1016/j.biopsych.2004.06.011 · DOI
- Daumann, 2005, Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users, Psychopharmacology (Berl.), 180, 607, 10.1007/s00213-004-2002-8 · DOI
- Davison, 1997, Ecstasy (MDMA) in recreational users: self-reported psychological and physiological effects, Hum. Psychopharmacol., 12, 221, 10.1002/(SICI)1099-1077(199705/06)12:3<221::AID-HUP854>3.0.CO;2-C · DOI · Paper page
- de la Torre, 2000, Pharmacology of MDMA in humans, Ann. N. Y. Acad. Sci., 914, 225, 10.1111/j.1749-6632.2000.tb05199.x · DOI · Paper page
- de la Torre, 2004, Clinical pharmacokinetics of amfetamine and related substances monitoring in conventional and non-conventional matrices, Clin. Pharmacokinet., 43, 157, 10.2165/00003088-200443030-00002 · DOI
- De Mei, 2009, Getting specialized: presynaptic and postsynaptic dopamine D2 receptors, Curr. Opin. Pharmacol., 9, 53, 10.1016/j.coph.2008.12.002 · DOI · Paper page
- Deng, 2007, Methamphetamine administration causes death of dopaminergic neurons in the mouse olfactory bulb, Biol. Psychiatry, 61, 1235, 10.1016/j.biopsych.2006.09.010 · DOI
- Derlet, 1990, Methamphetamine. Stimulant of the 1990s?, West. J. Med., 153, 625
- De Vito, 1989, Methamphetamine-induced neuronal damage: a possible role for free radicals, Neuropharmacology, 28, 1145, 10.1016/0028-3908(89)90130-5 · DOI · Paper page
- Di Iorio, 2012, Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users, Arch. Gen. Psychiatry, 69, 399, 10.1001/archgenpsychiatry.2011.156 · DOI
- Dickinson, 1999, Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum, J. Neurochem., 72, 148, 10.1046/j.1471-4159.1999.0720148.x · DOI · Paper page
- Donaldson, 2006, Oral health of the methamphetamine abuser, Am. J. Health-Syst. Pharm., 63, 2078, 10.2146/ajhp060198 · DOI · Paper page
- Downey, 2014, Altered energy production, lowered antioxidant potential, and inflammatory processes mediate CNS damage associated with abuse of the psychostimulants MDMA and methamphetamine, Eur. J. Pharmacol., 727, 125, 10.1016/j.ejphar.2014.01.032 · DOI
- Downing, 1986, The psychological and physiological effects of MDMA on normal volunteers, J. Psychoactive Drugs, 18, 335, 10.1080/02791072.1986.10472366 · DOI · Paper page
- Easton, 2003, Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy), Brain Res., 987, 144, 10.1016/S0006-8993(03)03319-5 · DOI
- Eisch, 1998, Methamphetamine neurotoxicity: dissociation of striatal dopamine terminal damage from parietal cortical cell body injury, Synapse, 30, 433, 10.1002/(SICI)1098-2396(199812)30:4<433::AID-SYN10>3.0.CO;2-O · DOI · Paper page
- Escobedo, 2005, A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice, Br. J. Pharmacol., 144, 231, 10.1038/sj.bjp.0706071 · DOI
- Espadas, 2012, l-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function, Neurobiol. Dis., 48, 271, 10.1016/j.nbd.2012.07.012 · DOI
- Esteban, 2001, 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose, Psychopharmacology (Berl.), 154, 251, 10.1007/s002130000645 · DOI · Paper page
- Fantegrossi, 2003, Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine (“ecstasy”) and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice, Psychopharmacology (Berl.), 166, 202, 10.1007/s00213-002-1261-5 · DOI
- Fantegrossi, 2008, A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse, Neuroscience, 151, 533, 10.1016/j.neuroscience.2007.11.007 · DOI
- Farfel, 1992, The antagonist MK-801 protects against serotonin depletions induced by methamphetamine 3,4-methylenedioxymethamphetamine and p-chloroamphetamine, Brain Res., 595, 121, 10.1016/0006-8993(92)91460-V · DOI
- Farré, 2004, Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics, Psychopharmacology (Berl.), 173, 364, 10.1007/s00213-004-1789-7 · DOI · Paper page
- Faunt, 1987, The effects of selective dopamine receptor agonists and antagonists on body temperature in rats, Eur. J. Pharmacol., 133, 243, 10.1016/0014-2999(87)90019-7 · doi:10.1016/0014-2999(87)90019-7
- Ferreira, 2013, Neurotoxicity of “ecstasy” and its metabolites in human dopaminergic differentiated SH-SY5Y cells, Toxicol. Lett., 216, 159, 10.1016/j.toxlet.2012.11.015 · DOI
- Finnegan, 1989, The N-methyl-d-aspartate (NMDA) receptor antagonist, dextrorphan, prevents the neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats, Neurosci. Lett., 105, 300, 10.1016/0304-3940(89)90637-X · DOI
- Fischer, 1995, Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/−)3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”), J. Neurosci., 15, 5476, 10.1523/JNEUROSCI.15-08-05476.1995 · DOI · Paper page
- Flaum, 1996, When does amphetamine-induced psychosis become schizophrenia?, Am. J. Psychiatry, 153, 812, 10.1176/ajp.153.6.812 · DOI · Paper page
- Fornai, 2004, DNA damage and ubiquitinated neuronal inclusions in the substantia nigra and striatum of mice following MDMA (ecstasy), Psychopharmacology (Berl.), 173, 353, 10.1007/s00213-003-1708-3 · DOI
- Frau, 2013, Contribution of caffeine to the psychostimulant, neuroinflammatory and neurotoxic effects of amphetamine-related drugs, J. Caffeine Res., 3, 79, 10.1089/jcr.2013.0007 · DOI
- Frau, 2013, Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility, J. Neurochem., 124, 69, 10.1111/jnc.12060 · DOI
- Frederick, 1995, Behavioral and neurochemical effects of chronic methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys, Neurotoxicol. Teratol., 17, 531, 10.1016/0892-0362(95)00013-H · DOI
- Frederick, 1998, Acute effects of fexfenfluramine (D-FEN) and methylenedioxymethamphetamine (MDMA) before and after short-course, high-dose treatment, Ann. N. Y. Acad. Sci., 844, 183, 10.1111/j.1749-6632.1998.tb08233.x · DOI
- Freudenmann, 2006, The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents, Addiction, 101, 1241, 10.1111/j.1360-0443.2006.01511.x · DOI · Paper page
- Friend, 2013, A role for D1 dopamine receptors in striatal methamphetamine-induced neurotoxicity, Neurosci. Lett., 555, 243, 10.1016/j.neulet.2013.08.039 · doi:10.1016/j.neulet.2013.08.039
- Fuller, 1992, Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist, Neuropharmacology, 31, 1027, 10.1016/0028-3908(92)90104-W · doi:10.1016/0028-3908(92)90104-w
- Fumagalli, 1998, Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter, J. Neurosci., 18, 4861, 10.1523/JNEUROSCI.18-13-04861.1998 · DOI · Paper page
- Fumagalli, 1999, Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice, J. Neurosci., 19, 2424, 10.1523/JNEUROSCI.19-07-02424.1999 · DOI · Paper page
- Gangarossa, 2012, Characterization of dopamine D1 and D2 receptor-expressing neurons in the mouse hippocampus, Hippocampus, 22, 2199, 10.1002/hipo.22044 · DOI · Paper page
- Gao, 2008, Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression, Trends Immunol., 29, 357, 10.1016/j.it.2008.05.002 · DOI · Paper page
- Garwood, 2006, Amphetamine exposure is elevated in Parkinson's disease, Neurotoxicology, 27, 1003, 10.1016/j.neuro.2006.03.015 · DOI
- Gaugler, 2012, Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity, Acta Neuropathol., 123, 653, 10.1007/s00401-012-0963-y · DOI
- Giros, 1989, Alternative splicing directs the expression of twoD2 dopamine receptor isoforms, Nature, 342, 923, 10.1038/342923a0 · DOI · Paper page
- Golembiowska, 2003, Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats, Neuropharmacology, 45, 484, 10.1016/S0028-3908(03)00209-0 · doi:10.1016/s0028-3908(03)00209-0
- Gonzalez-Aparicio, 2014, Oleoylethanolamide reduces l-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson's disease, Neurobiol. Dis., 62, 416, 10.1016/j.nbd.2013.10.008 · DOI · Paper page
- Gordon, 1991, Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat, Pharmacol. Biochem. Behav., 38, 339, 10.1016/0091-3057(91)90288-D · DOI · Paper page
- Górska, 2014, The effect of caffeine on MDMA-induced hydroxyl radical production in the mouse striatum, Pharmacol. Rep., 66, 718, 10.1016/j.pharep.2014.03.003 · doi:10.1016/j.pharep.2014.03.003
- Górska, 2014, The role of adenosine A1 and A2A receptors in the caffeine effect on MDMA-induced DA and 5-HT release in the mouse striatum, Neurotox. Res.
- Gouzoulis-Mayfrank, 2003, Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users, Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, 819, 10.1016/S0278-5846(03)00114-3 · DOI
- Granado, 2008, D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-induced arc and zif268 expression in the hippocampus, Cereb. Cortex, 18, 1, 10.1093/cercor/bhm026 · DOI · Paper page
- Granado, 2008, Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice, J. Neurochem., 107, 1102, 10.1111/j.1471-4159.2008.05705.x · DOI
- Granado, 2008, Early loss of dopaminergic terminals in striosomes after MDMA administration to mice, Synapse, 62, 80, 10.1002/syn.20466 · DOI
- Granado, 2010, Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration: early loss of TH in striosomes after methamphetamine, Neurotox. Res., 18, 48, 10.1007/s12640-009-9106-1 · DOI
- Granado, 2011, Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA, Neurobiol. Dis., 42, 391, 10.1016/j.nbd.2011.01.033 · DOI
- Granado, 2011, Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum, Glia, 59, 1850, 10.1002/glia.21229 · DOI
- Granado, 2013, Methamphetamine and Parkinson's disease, Parkinson's Dis., 10.1155/2013/308052 · DOI
- Granado, 2014, D1 but not D4 dopamine receptors are critical for MDMA-induced neurotoxicity in mice, Neurotox. Res., 25, 100, 10.1007/s12640-013-9438-8 · DOI
- Grant, 2012, Methamphetamine-associated psychosis, J. Neuroimmune Pharmacol., 7, 113, 10.1007/s11481-011-9288-1 · DOI · Paper page
- Green, 1992, The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: evidence for the protective effect of chlormethiazole, Neuropharmacology, 31, 315, 10.1016/0028-3908(92)90062-T · DOI
- Green, 2002, On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA, Psychopharmacology (Berl.), 164, 448, 10.1007/s00213-002-1158-3 · DOI
- Green, 2004, A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response, Eur. J. Pharmacol., 500, 3, 10.1016/j.ejphar.2004.07.006 · DOI · Paper page
- Green, 2005, Studies on the effect of MDMA (‘ecstasy’) on the body temperature of rats housed at different ambient room temperatures, Br. J. Pharmacol., 146, 306, 10.1038/sj.bjp.0706318 · DOI
- Green, 2012, Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans, Br. J. Pharmacol., 166, 1523, 10.1111/j.1476-5381.2011.01819.x · DOI · Paper page
- Gross, 2011, Striatal dopamine D1 and D2 receptors: widespread influences on methamphetamine-induced dopamine and serotonin neurotoxicity, Synapse, 65, 1144, 10.1002/syn.20952 · DOI
- Gudelsky, 1986, Suppression of the hypo- and hyperthermic responses to 5-HT agonists following the repeated administration of monoamine oxidase inhibitors, Psychopharmacology (Berl.), 90, 403, 10.1007/BF00179199 · DOI
- Gudelsky, 1996, Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin, J. Neural Transm., 102, 1397, 10.1007/BF01271253 · DOI
- Gudelsky, 2008, Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons, Pharmacol. Biochem. Behav., 90, 198, 10.1016/j.pbb.2007.10.003 · DOI
- Guilarte, 2003, Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity, Neuroscience, 122, 499, 10.1016/S0306-4522(03)00476-7 · DOI
- Guillot, 2008, Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis, J. Neurochem., 106, 2205, 10.1111/j.1471-4159.2008.05568.x · DOI
- Hadlock, 2010, Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation, J. Pharmacol. Exp. Ther., 335, 207, 10.1124/jpet.110.166660 · DOI
- Hall, 2006, Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management, Br. J. Anaesth., 96, 678, 10.1093/bja/ael078 · DOI · Paper page
- Hansen, 2002, Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity, J. Pharmacol. Exp. Ther., 300, 1093, 10.1124/jpet.300.3.1093 · DOI
- Hardman, 1973, Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals, Toxicol. Appl. Pharmacol., 25, 229, 10.1016/S0041-008X(73)80016-X · DOI
- Hatzidimitriou, 1999, Altered serotonin innervations patterns in the forebrain of monkeys treated with (+/−)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery, J. Neurosci., 19, 5096, 10.1523/JNEUROSCI.19-12-05096.1999 · DOI · Paper page
- Hedreen, 1995, Early loss of neostriatal striosome neurons in Huntington's disease, J. Neuropathol. Exp. Neurol., 54, 105, 10.1097/00005072-199501000-00013 · DOI · Paper page
- Henley, 1989, Localization and quantitative autoradiography of glutamatergic ligand binding sites in chick brain, Eur. J. Neurosci., 1, 516, 10.1111/j.1460-9568.1989.tb00358.x · DOI
- Hernandez-Rabaza, 2010, Neurotoxicity and persistent cognitive deficits induced by combined MDMA and alcohol exposure in adolescent rats, Addict. Biol., 15, 413, 10.1111/j.1369-1600.2010.00259.x · DOI
- Herndon, 2014, Glial cell response to 3,4-(+/−)-methylenedioxymethamphetamine and its metabolites, Toxicol. Sci., 138, 130, 10.1093/toxsci/kft275 · DOI
- Hirata, 1997, P53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies, J. Neurochem., 69, 780, 10.1046/j.1471-4159.1997.69020780.x · DOI · Paper page
- Huang, 2015, Caspase-11 plays an essential role in methamphetamine-induced dopaminergic neuron apoptosis, Toxicol Sci., 10.1093/toxsci/kfv014 · DOI
- Hurley, 2013, Neuroinflammation, neurodegeneration, and depression, Neurotox. Res., 23, 131, 10.1007/s12640-012-9348-1 · DOI · Paper page
- Hurtig, 2000, Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease, Neurology, 54, 1916, 10.1212/WNL.54.10.1916 · DOI · Paper page
- Imam, 2001, Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase, J. Neurochem., 76, 745, 10.1046/j.1471-4159.2001.00029.x · DOI · Paper page
- Insel, 1989, 3,4-Methylenedioxymethamphetamine (“ecstasy”) selectively destroys brain serotonin terminals in rhesus monkeys, J. Pharmacol. Exp. Ther., 249, 713, 10.1016/S0022-3565(25)23487-5 · DOI · Paper page
- Iravani, 2005, A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets, Eur. J. Neurosci., 21, 841, 10.1111/j.1460-9568.2005.03915.x · DOI
- Itzhak, 2003, Relevance of MDMA (“ecstasy”)-induced neurotoxicity to long-lasting psychomotor stimulation in mice, Psychopharmacology (Berl.), 166, 241, 10.1007/s00213-002-1320-y · DOI
- Izco, 2010, Administration of neurotoxic doses of MDMA reduces sensitivity to ethanol and increases GAT-1 immunoreactivity in mice striatum, Psychopharmacology (Berl.), 207, 671, 10.1007/s00213-009-1699-9 · DOI
- Jacobs, 1999, Activity of serotonergic neurons in behaving animals, Neuropsychopharmacology, 21, 9S, 10.1016/S0893-133X(99)00012-3 · DOI · Paper page
- Jayanthi, 1999, Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (Ecstasy), Neuroscience, 91, 1379, 10.1016/S0306-4522(98)00698-8 · DOI
- Jayanthi, 2005, Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis, Proc. Natl. Acad. Sci. U. S. A., 102, 868, 10.1073/pnas.0404990102 · DOI · Paper page
- Jiang, 2014, The effects of a low and escalating dosing regimen of methamphetamine on spontaneous behaviors of rhesus macaques (Macaca mulatta), Drug Alcohol Depend., 140, e86, 10.1016/j.drugalcdep.2014.02.280 · doi:10.1016/j.drugalcdep.2014.02.280
- Jiang, 2014, Epigenetic upregulation of alpha-synuclein in the rats exposed to methamphetamine, Eur. J. Pharmacol., 745, 243, 10.1016/j.ejphar.2014.10.043 · doi:10.1016/j.ejphar.2014.10.043
- Johnson, 2005, Acute hypercarbic gas exposure reveals functionally distinct subpopulations of serotonergic neurons in rats, J. Psychopharmacol., 19, 327, 10.1177/0269881105053281 · DOI · Paper page
- Kelly, 2012, Chronic exposure to corticosterone enhances the neuroinflammatory and neurotoxic responses to methamphetamine, J. Neurochem., 122, 995, 10.1111/j.1471-4159.2012.07864.x · DOI · Paper page
- Khairnar, 2010, Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine (‘ecstasy’) in mouse brain, Neurotox. Res., 17, 435, 10.1007/s12640-009-9125-y · DOI
- Khairnar, 2014, Antagonism of adenosine A1 or A2A receptors amplifies the effects of MDMA on glial activation in the mouse brain: relevance to caffeine–MDMA interactions, J. Caffeine Res., 4, 41, 10.1089/jcr.2014.0006 · DOI
- Kindlundh-Högberg, 2007, Repeated intermittent MDMA binges reduce DAT density in mice and SERT density in rats in reward regions of the adolescent brain, Neurotoxicology, 28, 1158, 10.1016/j.neuro.2007.07.002 · DOI
- King, 2010, Psychiatric symptoms and HPA axis function in adolescent methamphetamine users, J. Neuroimmune Pharmacol., 5, 582, 10.1007/s11481-010-9206-y · DOI
- Kish, 2010, Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study, Brain, 133, 1779, 10.1093/brain/awq103 · DOI · Paper page
- Kovács, 2007, Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in Dark Agouti rat brain and spinal cord, Neuropathol. Appl. Neurobiol., 33, 193, 10.1111/j.1365-2990.2006.00790.x · DOI
- Krasnova, 2009, Methamphetamine toxicity and messengers of death, Brain Res. Rev., 60, 379, 10.1016/j.brainresrev.2009.03.002 · DOI · Paper page
- Krasnova, 2014, Incubation of methamphetamine and palatable food craving after punishment-induced abstinence, Neuropsychopharmacology, 39, 2008, 10.1038/npp.2014.50 · DOI
- Kvernmo, 2006, A review of the receptor binding and pharmacokinetic properties of dopamine agonists, Clin. Ther., 28, 1065, 10.1016/j.clinthera.2006.08.004 · DOI · Paper page
- Leonardi, 1994, MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac), Neuropsychopharmacology, 10, 231, 10.1038/npp.1994.26 · DOI · Paper page
- Li, 2013, Depression and alterations in hypothalamic-pituitary-adrenal and hypothalamic-pituitary-thyroid axis function in male abstinent methamphetamine abusers, Hum. Psychopharmacol., 28, 477, 10.1002/hup.2335 · DOI
- Lim, 2014, Striatal cholinergic interneuron regulation and circuit effects, Front. Synaptic Neurosci., 21, 6
- Lipton, 1994, Mechanisms of disease: excitatory amino acids as a final common pathway for neurologic disorders, N. Engl. J. Med., 330, 613, 10.1056/NEJM199403033300907 · DOI · Paper page
- Liu, 2009, Alpha-synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity, Neurosci. Lett., 454, 187, 10.1016/j.neulet.2009.02.056 · DOI · Paper page
- Lopez-Rodriguez, 2014, Sex-dependent long-term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats, Br. J. Pharmacol., 171, 1435, 10.1111/bph.12519 · DOI · Paper page
- Lyles, 2003, Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms, Brain Res. Rev., 42, 155, 10.1016/S0165-0173(03)00173-5 · DOI · Paper page
- Malberg, 1996, Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat, J. Pharmacol. Exp. Ther., 278, 258, 10.1016/S0022-3565(25)20131-8 · DOI
- Manning-Boğ, 2007, Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter, Neurobiol. Dis., 27, 141, 10.1016/j.nbd.2007.03.014 · DOI
- Martín, 2008, Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors, Neuropsychopharmacology, 33, 1667, 10.1038/sj.npp.1301558 · DOI
- Mata, 2015, Methamphetamine decreases CD4 T cell frequency and alters pro-inflammatory cytokine production in a model of drug abuse, Eur. J. Pharmacol., 752C, 26, 10.1016/j.ejphar.2015.02.002 · DOI
- McCann, 1999, Cognitive performance in (+/−)3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study, Psychopharmacology (Berl.), 143, 417, 10.1007/s002130050967 · DOI · Paper page
- McCann, 2001, Caveat emptor: editors beware, Neuropsychopharmacology, 24, 333, 10.1016/S0893-133X(00)00171-8 · DOI
- McCann, 2008, Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/−)3,4-methylenedioxymethamphetamine (“ecstasy”) users: relationship to cognitive performance, Psychopharmacology (Berl.), 200, 439, 10.1007/s00213-008-1218-4 · DOI · Paper page
- McGuinness, 2006, Methamphetamine abuse, Am. J. Nurs., 106, 54, 10.1097/00000446-200612000-00024 · DOI
- McNamara, 2006, Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines. MDMA (“Ecstasy”) and MDA (“Love”), Neuropharmacology, 50, 69, 10.1016/j.neuropharm.2005.08.006 · DOI
- Mechan, 2002, The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA “ecstasy”) to rats, Br. J. Pharmacol., 135, 170, 10.1038/sj.bjp.0704442 · DOI · Paper page
- Medina, 1996, Differential abundance of glutamate transporter subtypes in amyotrophic lateral sclerosis (ALS)-vulnerable versus ALS resistant brain stem motor cell groups, Exp. Neurol., 142, 287, 10.1006/exnr.1996.0198 · DOI
- Melega, 1997, Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey, Brain Res., 766, 113, 10.1016/S0006-8993(97)00548-9 · DOI
- Melega, 2008, Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles, Neuropsychopharmacology, 33, 1441, 10.1038/sj.npp.1301502 · DOI
- Meredith, 2005, Implications of chronic methamphetamine use: a literature review, Harv. Rev. Psychiatry, 13, 141, 10.1080/10673220591003605 · DOI · Paper page
200 of 319 shown
Cited by
Methamphetamine-Induced Neuronal Damage: Neurotoxicity and Neuroinflammation
Kim, B., Yun, J., & Park, B. (2020) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2020.044 · Cited by 116
Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine
Dunlap, L. E., Andrews, A. M., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00155 · Cited by 106
mTOR Modulates Methamphetamine‐Induced Toxicity through Cell Clearing Systems
Lazzeri, G., Biagioni, F., Fulceri, F., Busceti, C. L., Scavuzzo, M. C., Ippolito, C., Salvetti, A., Lenzi, P., & Fornai, F. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6124745 · Cited by 53
Metadata
- Authors
- Moratalla, R., Khairnar, A., Simola, N., Granado, N., García-Montes, J. R., Porceddu, P. F., Tizabi, Y., Costa, G., & Morelli, M.
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 155
- Pages
- 149-170
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W2194633751
- Cited by
- 225
- References
- 24
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. https://app.cochat.ai/papers/10.1016/j.pneurobio.2015.09.011
- The paper
- Moratalla, R., Khairnar, A., Simola, N., Granado, N., García-Montes, J. R., Porceddu, P. F., Tizabi, Y., Costa, G., & Morelli, M. (2017). Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. Progress in Neurobiology. https://doi.org/10.1016/j.pneurobio.2015.09.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.